Richard Ac Hughes

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
    J Peripher Nerv Syst 11:30-46. 2006
  2. pmc Peripheral neuropathy
    Richard A C Hughes
    Department of Neuroimmunology, Guy s Campus, Guy s, King s, and St Thomas s School of Medicine, London SE1 1UL
    BMJ 324:466-9. 2002
  3. ncbi Guillain-Barré syndrome
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Hospital, UK
    Lancet 366:1653-66. 2005
  4. ncbi European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher
    R A C Hughes
    King s College London School of Medicine, London, UK
    Eur J Neurol 13:326-32. 2006
  5. ncbi No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000
    Richard A Hughes
    Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Campus, London, England
    Arch Intern Med 166:1301-4. 2006
  6. ncbi Immunotherapy for Guillain-Barré syndrome: a systematic review
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Campus, London, UK
    Brain 130:2245-57. 2007
  7. doi Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
    Lancet Neurol 7:136-44. 2008
  8. doi Treating nerves: a call to arms
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, London, UK
    J Peripher Nerv Syst 13:105-11. 2008
  9. doi Advances in the use of IVIg in neurological disorders
    Richard Hughes
    Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, SE1 1UL, UK
    J Neurol 255:1-2. 2008
  10. doi The role of IVIg in autoimmune neuropathies: the latest evidence
    Richard Hughes
    Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, SE1 1UL, UK
    J Neurol 255:7-11. 2008

Collaborators

Detail Information

Publications35

  1. ncbi Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
    J Peripher Nerv Syst 11:30-46. 2006
    ..Corticosteroids, intravenous immunoglobulin and plasma exchange each provide short term benefit but the possible long-term benefits of immunosuppressive drugs have yet to be confirmed in randomised, controlled trials...
  2. pmc Peripheral neuropathy
    Richard A C Hughes
    Department of Neuroimmunology, Guy s Campus, Guy s, King s, and St Thomas s School of Medicine, London SE1 1UL
    BMJ 324:466-9. 2002
  3. ncbi Guillain-Barré syndrome
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Hospital, UK
    Lancet 366:1653-66. 2005
    ..Further research is needed to discover treatments to prevent 20% of patients from being left with persistent and significant disability...
  4. ncbi European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher
    R A C Hughes
    King s College London School of Medicine, London, UK
    Eur J Neurol 13:326-32. 2006
    ....
  5. ncbi No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000
    Richard A Hughes
    Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Campus, London, England
    Arch Intern Med 166:1301-4. 2006
    ..Our goal was to determine whether immunization is associated with the incidence of Guillain-Barré syndrome (GBS)...
  6. ncbi Immunotherapy for Guillain-Barré syndrome: a systematic review
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Campus, London, UK
    Brain 130:2245-57. 2007
    ..Since approximately 20% of patients die or have persistent disability despite immunotherapy, more research is needed to identify better treatment regimens and new therapeutic strategies...
  7. doi Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
    Lancet Neurol 7:136-44. 2008
    ..We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP...
  8. doi Treating nerves: a call to arms
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, London, UK
    J Peripher Nerv Syst 13:105-11. 2008
    ..The Peripheral Nerve Society has formed a standing committee, the Inflammatory Neuropathy Consortium (http://pns.ucsd.edu/INC.htm), to facilitate the trials needed to answer the remaining questions in the inflammatory neuropathies...
  9. doi Advances in the use of IVIg in neurological disorders
    Richard Hughes
    Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, SE1 1UL, UK
    J Neurol 255:1-2. 2008
  10. doi The role of IVIg in autoimmune neuropathies: the latest evidence
    Richard Hughes
    Cochrane Neuromuscular Disease Review Group, Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, SE1 1UL, UK
    J Neurol 255:7-11. 2008
    ..011). On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP. For MMN, although the evidence for IVIg is limited, there is no evidence to recommend other treatments...
  11. doi Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial
    Richard A C Hughes
    Department of Clinical Neuroscience, Institute of Psychiatry, King s College London, London SE5 8AF, UK
    Expert Rev Neurother 9:789-95. 2009
    ..Adverse events were mostly mild and serious adverse events were not more common with IVIg than with placebo. The results persuaded the US FDA and Health Canada to approve Gamunex for use in CIDP...
  12. ncbi Supportive care for patients with Guillain-Barré syndrome
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College, London, England
    Arch Neurol 62:1194-8. 2005
    ..More research is needed to identify optimal methods for all aspects of supportive care...
  13. ncbi Campylobacter jejuni in Guillain-Barré syndrome
    Richard Hughes
    Department of Clinical Neurosciences, Guy s King s and St Thomas School of Medicine, King s College, London, UK
    Lancet Neurol 3:644. 2004
  14. ncbi Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit?
    Richard A C Hughes
    Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, SE1 1 UL, London, UK
    Lancet 363:181-2. 2004
  15. ncbi Interferon beta 1a for secondary progressive multiple sclerosis
    Richard A C Hughes
    Department of Neuroimmunology, Guy s, King s and St Thomas School of Medicine, Guy s Hospital, London SE1 1 UL, UK
    J Neurol Sci 206:199-202. 2003
    ..These conclusions should be reviewed when the full results of all four trials have been published...
  16. ncbi A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy
    R A C Hughes
    Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, London SE1 1UL, UK
    Brain 127:1723-30. 2004
    ..A logistic regression analysis identified environmental toxin exposure and hypertriglyceridaemia, but not glucose intolerance or alcohol overuse as significant risk factors that deserve further investigation as possible causes of CIAP...
  17. ncbi Management of chronic inflammatory demyelinating polyradiculoneuropathy
    Richard A C Hughes
    Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, London, UK
    Drugs 63:275-87. 2003
    ..General measures to rehabilitate patients and manage symptoms, including foot drop, weak hands, fatigue and pain, are important...
  18. ncbi Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
    Mohamed Mahdi-Rogers
    Department of Neurology, King s College Hospital, Denmark Hill, London, UK, SE5 9RS
    Cochrane Database Syst Rev 11:CD003280. 2010
    ..It is probably due to an autoimmune process. Immunosuppressive or immunomodulatory drugs would be expected to be beneficial...
  19. ncbi Corticosteroids for Guillain-Barré syndrome
    Richard Ac Hughes
    MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, PO Box 114, Queen Square, London, UK, WC1N 1BG
    Cochrane Database Syst Rev 2:CD001446. 2010
    ..According to low quality evidence oral corticosteroids delay recovery. Diabetes requiring insulin was significantly more and hypertension less common with corticosteroids...
  20. ncbi Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
    Paul McCrone
    Centre for the Economics of Mental Health, Health Services Research Department, Institute of Psychiatry, King s College London, UK
    Eur J Neurol 10:687-94. 2003
    ..The impact of later side-effects of prednisolone on long-term costs and quality of life are likely to reduce the cost per QALY of IVIg treatment...
  21. pmc Systematic reviews to help guide clinical practice in neuromuscular disease
    Kate Jewitt
    Cochrane Neuromuscular Disease Group, Department of Neuroimmunology, Guy s, King s and St Thomas School of Medicine, Guy s Campus, London, UK
    J Neurol Neurosurg Psychiatry 74:ii43-ii44. 2003
  22. doi Intravenous immunoglobulin for Guillain-Barré syndrome
    Richard A C Hughes
    MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK
    Cochrane Database Syst Rev 7:CD002063. 2012
    ..Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective...
  23. doi Corticosteroids for Guillain-Barré syndrome
    Richard A C Hughes
    MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK
    Cochrane Database Syst Rev 8:CD001446. 2012
    ..Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit...
  24. ncbi Brain-derived neurotrophic factor in experimental autoimmune neuritis
    Paul A Felts
    Department of Neuroimmunology and the Neuroinflammation Research Group, Guy s, King s and St Thomas School of Medicine, King s College London, Guy s Campus, London SE1 1UL, UK
    J Neuroimmunol 124:62-9. 2002
    ..With the exception of a possibly protective effect indicated by bladder weight, this study suggests that BDNF may not provide an effective therapy for GBS, at least in the acute phase of the disease...
  25. ncbi A clinical prognostic scoring system for Guillain-Barré syndrome
    Rinske van Koningsveld
    Department of Neurology, Erasmus MC, Rotterdam, Netherlands
    Lancet Neurol 6:589-94. 2007
    ..We aimed to develop and validate a scoring system based on clinical characteristics in the acute phase of GBS to predict outcome at 6 months...
  26. pmc Management of inflammatory neuropathies
    Robert D M Hadden
    West London Neurosciences Centre, Charing Cross Hospital, London, UK
    J Neurol Neurosurg Psychiatry 74:ii9-ii14. 2003
  27. ncbi Increased incidence of carpal tunnel syndrome up to 10 years before diagnosis of diabetes
    Martin C Gulliford
    Division of Health and Social Care Research, King s College, London, UK
    Diabetes Care 29:1929-30. 2006
  28. ncbi Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy
    David Allen
    Department of Clinical Neurosciences, Guy s Campus, Guy s, King s and St Thomas School of Medicine, King s College, Denmark Hill, London SE5 9RS, UK
    J Peripher Nerv Syst 10:174-80. 2005
    ..Six CIDP and seven GBS patients' sera reacted with this band. These results support the view that antibodies to myelin proteins, and especially P0, are present in the serum of some patients with CIDP and GBS...
  29. ncbi Guillain-Barré syndrome
    Jane Pritchard
    Department of Clinical Neurosciences, Guy s Hospital, Guy s, King s and St Thomas School of Medicine, London SE1 1UL, UK
    Lancet 363:2186-8. 2004
  30. ncbi Cochrane systematic reviews of treatments for peripheral nerve disorders
    Richard A C Hughes
    J Peripher Nerv Syst 9:127-9. 2004
  31. ncbi Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing
    Michael P T Lunn
    Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Brain 125:904-11. 2002
    ..8+/-4.6 nm). This reinforces the hypothesis that MAG is involved in the control of neurofilament spacing through sidearm phosphorylation and demonstrates a MAG-mediated pathogenic effect of the anti-MAG antibody in peripheral nerves...
  32. ncbi Reduced circulating CD4+CD25+ cell populations in Guillain-Barré syndrome
    Jane Pritchard
    Department of Clinical Neuroscience, King s College London School of Medicine, Guy s Campus, London SE1 1UL, UK
    J Neuroimmunol 183:232-8. 2007
    ..4%, 95% CI 1.1-1.8%, p=0.005. Since CD4+CD25+ cells include cells with special immunoregulatory functions, further investigation of this phenomenon and its relation to possible loss of regulatory T cell function in GBS is warranted...
  33. pmc Treating nerves: from anecdote to systematic review
    Richard A C Hughes
    Department of Clinical Neurosciences, Guy s, King s and St Thomas School of Medicine, London SE1 1UL, UK
    J R Soc Med 96:432-5. 2003
  34. ncbi Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms
    Nina M van Sorge
    Department of Neurology G03 228, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Neuroimmunol 162:157-64. 2005
    ..Results suggest that Fc gammaRIII genotypes may represent mild disease-modifying factors in GBS...